High importance
Nov 13, 2026
To evaluate the efficacy of engasertib 40 mg once daily in reducing the frequency of epistaxis in patients with moderate to severe Hereditary Hemorrhagic Telangiectasia (HHT) over a 28-week period.
HHT stands for Hereditary Hemorrhagic Telangiectasia (also called Osler-Weber-Rendu syndrome). It is a rare genetic disorder that causes blood vessels to form improperly. These weak vessels link arteries and veins directly without tiny vessels in between. This leads to easy bleeding
Sources last checked: November 16, 2026
November 16, 2026
A study is examining the surgical risks for patients with hereditary hemorrhagic telangiectasia who have heart infections and unusual bleeding issues. This research may help in understanding how to approach these complex cases (Item 1).
Materials
88 materials
High importance
Nov 13, 2026
To evaluate the efficacy of engasertib 40 mg once daily in reducing the frequency of epistaxis in patients with moderate to severe Hereditary Hemorrhagic Telangiectasia (HHT) over a 28-week period.
Nov 12, 2026
This study aims to explore the risks of surgery in patients with hereditary hemorrhagic telangiectasia (HHT) who have endocarditis, which is an infection of the heart's inner lining, and unusual bleeding issues.
High importance
Nov 12, 2026
To identify somatic genetic mutations activating the MAPK signaling pathway in brain arteriovenous malformations (bAVMs) using liquid biopsies, aiming to enhance non-invasive diagnostic capabilities and therapeutic options.
High importance
Nov 7, 2026
The study aims to create a machine learning model that predicts the presence of brain arteriovenous malformations (bAVMs) in patients with hereditary hemorrhagic telangiectasia (HHT). This could help identify those who need closer monitoring for cerebrovascular issues.
High importance
Nov 6, 2026
This report aims to describe a rare case of Hereditary Hemorrhagic Telangiectasia (HHT) affecting the tongue, which can provide vital information for dental practitioners.
High importance
Nov 6, 2026
To evaluate the efficacy and safety of ATV-1601 in patients with moderate to severe Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Nov 6, 2026
To evaluate the safety and efficacy of the topical application of TOR-582 (sirolimus) for managing epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT).
Nov 4, 2026
This research focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a genetic condition that causes abnormal blood vessel growth, leading to potential bleeding issues.
High importance
Oct 31, 2026
The study aimed to evaluate how well polidocanol sclerotherapy treats nosebleeds in people with Hereditary Hemorrhagic Telangiectasia (HHT).
Oct 30, 2026
The study aims to improve how we classify genetic changes (variants) in the ACVRL1 gene, which is linked to hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension. This is important because some variants are not clearly understood, making it hard to know if they are harmful or not.
High importance
Oct 27, 2026
To study whether daily use of Pazopanib over 24 weeks can reduce the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
High importance
Oct 22, 2026
To consolidate current knowledge on the molecular and genetic mechanisms behind cerebral arteriovenous malformations (AVMs), particularly inherited syndromes and sporadic lesions, and to identify potential therapeutic targets.
High importance
Oct 22, 2026
To evaluate health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Oct 21, 2026
To determine the frequency of obstructive sleep apnea (OSA) diagnoses in patients with hereditary hemorrhagic telangiectasia (HHT).
High importance
Oct 14, 2026
To evaluate the impact of hereditary hemorrhagic telangiectasia (HHT) on heavy menstrual bleeding (HMB) in adolescents and young adults (AYAs).
High importance
Oct 13, 2026
To evaluate the effectiveness of low energy long pulse 1064 nm Nd:YAG laser treatment for vascular anomalies associated with hereditary hemorrhagic telangiectasia (HHT) using optical coherence tomography (OCT).
High importance
Oct 11, 2026
To review emerging novel therapies for hereditary hemorrhagic telangiectasia (HHT), focusing on investigational agents that target the vascular and hemostatic systems.
High importance
Oct 8, 2026
To report and discuss a rare case of hemoptysis in a patient with a significant medical history related to Hereditary Hemorrhagic Telangiectasia (HHT), specifically focusing on the implications of SMAD4 and ENG mutations.
High importance
Oct 7, 2026
This case report aims to highlight the diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT) in a patient with a long history of iron deficiency anemia and recurrent bleeding.
High importance
Oct 7, 2026
To investigate the role of RUNX3 in endothelial cells and its impact on vascular stability and angiogenesis.
High importance
Oct 7, 2026
To assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT), as well as its effects on reducing the need for blood or iron treatments and improving blood counts.
High importance
Oct 5, 2026
To highlight a rare case of subarachnoid hemorrhage (SAH) in a pediatric patient with hereditary hemorrhagic telangiectasia (HHT) and review existing literature on such occurrences.
High importance
Oct 3, 2026
To report a case of a patient with a novel GDF2 mutation associated with Hereditary Hemorrhagic Telangiectasia (HHT) complicated by acute cerebral infarction.
High importance
Oct 2, 2026
To evaluate the natural history and growth patterns of brain arteriovenous malformations (bAVMs) in patients with Hereditary Hemorrhagic Telangiectasia (HHT) through a longitudinal study using serial MRIs.
High importance
Oct 2, 2026
To evaluate the comparative effectiveness of different management strategies for unruptured brain arteriovenous malformations (AVMs) in order to guide clinical decision-making.
High importance
Oct 1, 2026
To evaluate an uncommon case of resistant hypertension attributed to a renal arteriovenous malformation (rAVM) and the outcomes following nephrectomy.
High importance
Oct 1, 2026
To investigate the role of c-KIT in vascular pathology associated with Hereditary Hemorrhagic Telangiectasia (HHT) and its potential as a therapeutic target.
High importance
Oct 1, 2026
To explore the mechanistic role of SMAD4 in regulating fluid shear stress (FSS) in vascular endothelial cells and its implications for arteriovenous malformations (AVMs) in hereditary hemorrhagic telangiectasia (HHT).
High importance
Sep 30, 2026
To evaluate the outcomes of a multimodal approach in treating a ruptured cerebellar arteriovenous malformation (AVM).
High importance
Sep 29, 2026
To report the successful treatment of a giant cervical arteriovenous malformation (AVM) in a child using coil-only transcatheter embolization.
High importance
Sep 28, 2026
To analyze and understand obstetrical complications associated with rare maternal vascular genetic disorders, specifically focusing on Hereditary Hemorrhagic Telangiectasia (HHT) and related conditions to improve maternal and fetal health outcomes.
High importance
Sep 27, 2026
To report the effectiveness of systemic bevacizumab in managing severe gastrointestinal bleeding in a patient with hereditary hemorrhagic telangiectasia (HHT).
High importance
Sep 26, 2026
To compare the effectiveness and tolerability of 532/1064-nm KTP/Nd: YAG laser versus 595-nm pulsed dye laser for treating various cutaneous vascular lesions, including conditions related to hereditary hemorrhagic telangiectasia (HHT).
High importance
Sep 25, 2026
To develop and validate a prediction model for neurological outcomes after microsurgical resection of brain arteriovenous malformations (AVMs).
High importance
Sep 25, 2026
To report a case of spontaneous rupture of the urinary bladder (SRUB) in a patient with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).
High importance
Sep 25, 2026
To review and summarize reported cases of pancreatic arteriovenous malformations (AVMs) in patients with hereditary hemorrhagic telangiectasia (HHT), providing insights into demographics, clinical presentations, diagnostic methods, treatments, and follow-up outcomes.
High importance
Sep 24, 2026
To report a pediatric case of multiple brain abscesses caused by Streptococcus intermedius as an initial manifestation of SMAD4-associated juvenile polyposis and hereditary hemorrhagic telangiectasia (HHT) overlap syndrome.
High importance
Sep 24, 2026
To investigate the pathogenesis of pulmonary vascular malformations (PVMs) in patients with single ventricle congenital heart disease and to identify shared mechanisms with hereditary hemorrhagic telangiectasia (HHT) arteriovenous malformations (AVMs).
High importance
Sep 23, 2026
To characterize 30-day postoperative outcomes following craniotomy for arteriovenous malformation (AVM) resection in pediatric patients and identify independent predictors of adverse events.
High importance
Sep 23, 2026
To review the current diagnostic and therapeutic paradigms for Hereditary Hemorrhagic Telangiectasia (HHT), focusing on systemic therapy and modern management strategies.
High importance
Sep 23, 2026
To profile circulating angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia (HHT) undergoing bevacizumab treatment and assess their relation to clinical severity and response to therapy.
High importance
Sep 22, 2026
To present a case of renal arteriovenous malformation (rAVM) in a patient with unexplained gross hematuria and to highlight the effectiveness of selective transcatheter embolization as a treatment.
High importance
Sep 22, 2026
To evaluate the difference in permanent neurological morbidity between surgical resection of hereditary hemorrhagic telangiectasia (HHT)-associated brain arteriovenous malformations (AVMs) and sporadic AVMs.
High importance
Sep 21, 2026
To evaluate a staged embolisation strategy for treating spinal epidural arteriovenous fistula (SEDAVF) in a patient with a concurrent pulmonary arteriovenous malformation (PAVM).
High importance
Sep 20, 2026
To evaluate the role of stereotactic radiosurgery (SRS) in the management of surgically inoperable cerebral arteriovenous malformations (AVMs) and to propose an individualized treatment framework.
High importance
Sep 18, 2026
To evaluate the efficacy and safety of bevacizumab for treating severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia (HHT) and to explore how clinical and genetic factors affect treatment outcomes.
High importance
Sep 17, 2026
To explore the role of extracellular matrix remodeling and internal elastic lamina (IEL) alterations in cerebral arteriovenous malformations (cAVMs) and their contributions to vascular wall biology and structural stability.
High importance
Sep 17, 2026
To explore the feasibility and implications of body donation for research in hereditary hemorrhagic telangiectasia (HHT), focusing on the analysis of human tissue samples with and without vascular malformations.
High importance
Sep 16, 2026
To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the investigational drug ALN-6400 in both healthy volunteers and adult patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Sep 14, 2026
To develop and evaluate a two-step genetic risk stratification model for brain arteriovenous malformations (bAVM) incorporating both rare Mendelian variants and a polygenic risk score (BAVM-PRS) to enhance screening efficiency.
High importance
Sep 13, 2026
To explore differences in expressivity and quantify the degree of phenotypic variability among individuals with hereditary hemorrhagic telangiectasia (HHT) carrying the same pathogenic variant.
High importance
Sep 11, 2026
To compare the efficacy and safety of various pharmacologic therapies in managing spontaneous epistaxis associated with Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Sep 11, 2026
To compare long-term hemorrhagic and functional outcomes between intervention and observation strategies for brain arteriovenous malformations (bAVMs).
High importance
Sep 11, 2026
To evaluate the long-term clinical outcomes of an accelerated volume-staged stereotactic radiosurgery (AVS-SRS) approach for treating large cerebral arteriovenous malformations (AVMs).
High importance
Sep 10, 2026
To report the case of a 69-year-old female with bilateral pulmonary arteriovenous malformations (PAVMs) incidentally found during CT imaging for appendicitis and treated via thoracoscopic surgery.
High importance
Sep 8, 2026
To report a case of gastric juvenile-type polyposis associated with a SMAD4 mutation and highlight the importance of genetic testing in diagnosing hereditary syndromes.
High importance
Sep 8, 2026
To evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT).
High importance
Sep 7, 2026
To generate and characterize two induced pluripotent stem cell (iPSC) lines from hereditary hemorrhagic telangiectasia (HHT) patients with specific ACVRL1 mutations.
High importance
Sep 6, 2026
To compare outcomes of microsurgical resection versus conservative management for unruptured brain arteriovenous malformations (AVMs) using post-ARUBA evidence.
High importance
Sep 3, 2026
To evaluate the safety of antithrombotic therapy (AT) in patients with hereditary hemorrhagic telangiectasia (HHT), focusing on bleeding outcomes.
High importance
Sep 2, 2026
To evaluate the efficacy of Selumetinib in treating pediatric arteriovenous malformations (AVMs) associated with a MAP2K1 variant.
High importance
Aug 26, 2026
To highlight the atypical presentation and delayed diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT) in a 71-year-old patient who did not exhibit recurrent epistaxis, thereby emphasizing the need for broader diagnostic considerations of HHT.
High importance
Aug 26, 2026
To clarify genetic diagnoses in patients presenting with symptoms resembling hereditary hemorrhagic telangiectasia - juvenile polyposis syndrome (HHT-JPS) versus familial adenomatous polyposis (FAP).
High importance
Aug 26, 2026
To evaluate the prevalence of hereditary haemorrhagic telangiectasia (HHT) using genetic data and machine learning techniques, compared to traditional clinical assessments.
High importance
Aug 26, 2026
To evaluate the effectiveness of topical intranasal therapies for managing epistaxis in patients with Hereditary Hemorrhagic Telangiectasia (HHT) and compare them to placebo treatments.
High importance
Aug 25, 2026
To report a rare case of ruptured pulmonary arteriovenous malformation (PAVM) during pregnancy that resulted in hemothorax and to emphasize the need for awareness and proper diagnostic modalities in emergency settings.
High importance
Aug 24, 2026
To inform about the FDA's decision to add a boxed warning to ferric carboxymaltose (FCM) regarding the risk of serious hypophosphatemia following a citizen petition led by Dr. Scott Olitsky from Cure HHT.
High importance
Aug 24, 2026
To examine the molecular and cellular mechanisms through which inflammatory pathways contribute to the development, rupture, and treatment response of brain arteriovenous malformations (bAVMs).
High importance
Aug 21, 2026
To evaluate the effectiveness of en bloc resection combined with trapezius island flap reconstruction in treating giant extracranial arteriovenous malformations (AVMs) in the orbital region.
High importance
Aug 21, 2026
To evaluate current evidence on systemic therapies for Hereditary Hemorrhagic Telangiectasia (HHT) and identify emerging therapeutic targets.
High importance
Aug 21, 2026
To evaluate the efficacy of selective venous ammonia sampling-guided embolization in treating refractory hepatic encephalopathy associated with intrahepatic portovenous shunts in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Aug 21, 2026
To investigate the clinical phenotypes and genetic variations associated with the ENG gene in four families affected by Hereditary Hemorrhagic Telangiectasia Type 1 (HHT1), particularly focusing on individuals with pulmonary arteriovenous malformations (PAVMs).
High importance
Aug 20, 2026
This study reports a pediatric case where Juvenile Polyposis/Hereditary Hemorrhagic Telangiectasia (HHT) syndrome was diagnosed through the manifestation of anemia associated with pulmonary arteriovenous malformations (PAVM).
High importance
Aug 19, 2026
To evaluate the prevalence and clinical implications of Hereditary Hemorrhagic Telangiectasia (HHT) in relation to the genes involved (ALK1, endoglin, SMAD4) and treatment modalities (bevacizumab, pomalidomide) for associated arteriovenous malformations.
High importance
Aug 19, 2026
To evaluate the use and effectiveness of bevacizumab as a treatment option for patients with hereditary hemorrhagic telangiectasia (HHT) in France.
High importance
Aug 18, 2026
To present a case of renal arteriovenous malformation (AVM) in a young patient with persistent hypertension, emphasizing the diagnostic challenges and the role of selective renal angiography.
High importance
Aug 18, 2026
To highlight the clinical management of a patient with hereditary hemorrhagic telangiectasia (HHT) presenting with refractory gastrointestinal bleeding and severe anemia.
High importance
Aug 18, 2026
To present a case of a 26-year-old man with recurrent syncope and an unexpected diagnosis of pulmonary arterial hypertension (PAH) associated with pulmonary arteriovenous malformations (AVMs), suggesting a link to hereditary hemorrhagic telangiectasia (HHT).
High importance
Aug 13, 2026
To develop a microphysiological system (HHT-on-a-chip) that mimics vascular lesions observed in patients with Hereditary Hemorrhagic Telangiectasia (HHT) to enhance understanding of the disease mechanisms and potential treatments.
High importance
Aug 11, 2026
The study reports a case of a young woman with hereditary hemorrhagic telangiectasia (HHT) who developed a brain abscess due to a previously undiagnosed pulmonary arteriovenous malformation (PAVM). The goal is to highlight the importance of diagnosing PAVMs in patients with HHT.
High importance
Jul 31, 2026
To analyze the dermoscopic features of capillary malformations associated with Capillary Malformation-Arteriovenous Malformation Syndrome Type 2.
High importance
Jul 30, 2026
To characterize the cellular composition of the immune microenvironment in brain arteriovenous malformations (bAVMs) at single-cell resolution and identify immune cell populations associated with angiogenesis and extracellular matrix remodeling.
High importance
Jul 30, 2026
To evaluate the effective dose of intranasal bevacizumab for treating epistaxis in patients with Hereditary Hemorrhagic Telangiectasia (HHT).
High importance
Jul 30, 2026
To establish a comprehensive institutional and population-based registry for Haemorrhagic Hereditary Telangiectasia (HHT) to improve understanding of its epidemiology, risk factors, clinical presentation, and treatment outcomes.
High importance
Jul 13, 2026
To evaluate the effectiveness of doxycycline in reducing epistaxis severity in patients with hereditary hemorrhagic telangiectasia (HHT), with a focus on genotype-stratified responses (specifically active receptor-like kinase 1, endoglin, and SMAD4).
High importance
Mar 25, 2026
To evaluate the effectiveness of nonsurgical management in treating a challenging auricular arteriovenous malformation (AVM) through serial embolization and sclerotherapy.
High importance
Feb 6, 2026
To evaluate the efficacy of a staged 'demarcation procedure' in reducing intraoperative bleeding and operative time during the definitive resection of large arteriovenous malformations (AVMs).
High importance
Jan 6, 2026
To evaluate the risk of postintervention hemorrhage following stereotactic radiosurgery (SRS) for cerebral arteriovenous malformations (AVMs) and to identify predictors of such events.